In accordance with the importance of Nrf2 down-regulation in tumour growth reduction and in enhancing the efficacy of chemotherapeutic agents [43], the use of t10,c12-CLA in combination with specific APEH/proteasome inhibitors could represent an effective strategy for melanoma treatment. The gene discussed is NFE2L2; the disease is melanoma.